Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James

Oncolytics Biotech (NASDAQ:ONCY) was upgraded by equities researchers at Raymond James to a “moderate buy” rating in a note issued to investors on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

A number of other equities research analysts have also recently issued reports on the stock. Leede Financial cut shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Oncolytics Biotech in a research note on Thursday.

Oncolytics Biotech Stock Performance

Oncolytics Biotech stock opened at $0.98 on Thursday. The company’s fifty day moving average price is $1.09 and its 200 day moving average price is $1.06. Oncolytics Biotech has a 1 year low of $0.84 and a 1 year high of $1.75. The stock has a market capitalization of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech as of its most recent SEC filing. Institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.